Cefotaxime in the treatment of pneumococcal pneumonia

Stephen G. Jenkinson, Michael S. Briggs, Randy D. Bryn

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Cefotaxime, 1000 mg intramuscularly twice daily, was compared with cefazolin sodium, 500 mg intramuscularly twice daily, in the treatment of 28 patients with uncomplicated pneumococcal pneumonia. Patients were randomly assigned to therapy with one-third being treated with cefazolin sodium and two-thirds being treated with cefotaxime. No patients experienced side-effects or allergic reactions after receiving cefotaxime. All patients admitted into the study recovered satisfactorily without relapses. Cefotaxime is safe and effective in the previously described dosage for the treatment of pneumococcal pneumonia.

Original languageEnglish (US)
Pages (from-to)177-180
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
StatePublished - 1980
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Cefotaxime in the treatment of pneumococcal pneumonia'. Together they form a unique fingerprint.

Cite this